Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD Inc (TXMD) is an innovative pharmaceutical company focused on advancing women's health through specialized therapies and strategic licensing partnerships. This page serves as the definitive source for all official company announcements, regulatory updates, and market developments.
Investors and industry professionals will find timely updates on TXMD's prescription products including IMVEXXY, BIJUVA, and ANNOVERA, along with financial disclosures and partnership agreements. Our curated news feed covers essential developments including FDA milestones, licensing expansions with commercial partners like Mayne Pharma, and clinical research advancements.
Key updates include earnings reports, product pipeline progress, intellectual property developments, and strategic initiatives in the women's healthcare sector. All content is verified through primary sources to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for direct access to TherapeuticsMD's latest press releases and objective news coverage. Check regularly for updates on pharmaceutical royalties, regulatory decisions, and market positioning within the competitive women's health landscape.
TherapeuticsMD, Inc. (NASDAQ: TXMD) reported its financial results for 2022, highlighting a significant turnaround with a net income of $1.1 million ($0.12 per share), compared to a net loss of $79.3 million in 2021. This improvement is attributed to increased licensing revenues from its exclusive agreement with Mayne Pharma, which amounted to $70 million in 2022, a steep rise from just $2.6 million the previous year. Operating expenses decreased to $67.4 million from $80.7 million in 2021, reflecting cost-cutting measures following the transaction with Mayne Pharma. However, cash reserves fell to $38.1 million from $64.9 million year-over-year. The company eliminated debt totaling $188.3 million after the Mayne Pharma deal, while also redeeming preferred stock. Future outlook remains focused on streamlining operations and potentially creating value through additional strategic initiatives.
TherapeuticsMD (TXMD) completed a significant transaction with Mayne Pharma, granting exclusive U.S. commercialization rights for its products and selling certain assets. TXMD received approximately
TherapeuticsMD, Inc. (TXMD) announced a strategic licensing agreement with Mayne Pharma for U.S. commercialization of its products. TXMD will receive approximately
TherapeuticsMD (TXMD) reported Q3 2022 revenues of $20.9 million, a $4.5 million decline year-over-year, despite a 10% growth in ANNOVERA prescriptions. Operating expenses decreased by $22 million to $37.9 million. The net loss for the quarter was $29 million ($3.13 per share), improved from a $47.4 million loss in Q3 2021. The company completed a $7 million investment from Rubric Capital, enhancing liquidity amid ongoing strategic assessments.
TherapeuticsMD, Inc. (NASDAQ: TXMD) announced a $7 million investment in Series A Preferred Stock from Rubric Capital Management LP. The funds will be used for working capital and extend the maturity date of a financing agreement with Sixth Street Specialty Lending, Inc. to
TherapeuticsMD (NASDAQ: TXMD) has secured a $7 million private investment in its Series A Preferred Stock from Rubric Capital Management. The funds are intended for working capital. The investment extends the maturity date of its financing agreement with Sixth Street Specialty Lending to October 31, 2022, with a potential further extension to November 30, 2022 if additional $7 million in equity capital is raised. The Company’s management continues to explore strategic alternatives to enhance its long-term financial position.
TherapeuticsMD, Inc. (NASDAQ: TXMD) has appointed Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-CEOs, succeeding Mr. Hugh O’Dowd. Dr. Bernick, a co-founder and previous Chief Scientific and Medical Officer, is expected to lead the company through a strategic alternatives process. Mr. Glickman, the former Chief Business Officer, brings 30 years of experience. Additionally, Tommy Thompson has transitioned to Executive Chairman from Chairman of the Board. The leadership change aims to enhance efforts to evaluate strategic options and deliver shareholder value.
TherapeuticsMD (TXMD) reported a solid Q2 2022 with total net revenue reaching $28.6 million, a 24% increase year-over-year. ANNOVERA revenue surged to $18.3 million, marking a 28% increase in prescriptions. Operating expenses dropped 21%, and the company achieved net income of $112.3 million, driven by a $143.4 million gain from divesting its vitaCare unit. Cash on hand decreased to $26.3 million by June 30, 2022, while $90.8 million remains under the financing agreement.
TherapeuticsMD, Inc. (NASDAQ: TXMD) will report its Q2 2022 financial results on August 15, 2022, at 8:30 a.m. ET. Executive management will host a conference call to discuss these results, accessible via audio conference line and a webcast. The live stream and a replay will be available on the TherapeuticsMD website for 30 days. The company focuses on developing healthcare products for women, addressing health issues related to family planning, reproductive health, and menopause management.
TherapeuticsMD (NASDAQ: TXMD) has secured a $15 million private investment from Rubric Capital Management to support its operating capital needs. This financing comes alongside an extension of its debt maturity date with Sixth Street Partners to September 30, 2022, with options for further extensions if additional equity of $7 million is raised.
The investment is anticipated to enable the company to continue meeting demand for its women's healthcare products while evaluating strategic options to enhance shareholder value.
FAQ
What is the current stock price of Therapeuticsmd (TXMD)?
What is the market cap of Therapeuticsmd (TXMD)?
